Celltrion Unveils Next-Generation ADC and Multi-Antibody Drug Vision at US JPM

Chairman Jungjin Seo Announces Future Growth Engines Including New Drugs at JPM
"Next-Generation ADCs and Multi-Antibody New Drugs to Drive Growth as Twin Engines"

Celltrion participated in the '2025 JP Morgan Healthcare Conference (JPM)' and revealed for the first time a detailed development roadmap for its new drug pipeline.

Seo Jung-jin, Chairman of Celltrion Group (right), and Seo Jin-seok, CEO of Celltrion Management Division, are conducting a Q&A session at the "2025 JP Morgan Healthcare Conference" held on the 14th (local time) in San Francisco, USA. Celltrion

On the 14th (local time), Celltrion disclosed its new drug development achievements and specific future development plans under the theme of 'Innovative New Drug Pipeline Development Strategy' on the main stage of the JPM event.

Jinseok Seo, CEO of Celltrion's Management Business Division, stated, "Celltrion has already demonstrated its antibody biopharmaceutical development capabilities externally by achieving early the vision of building an 11-product portfolio by 2025 last year." He added, "Based on the accumulated experience and know-how in antibody drug development, Celltrion will accelerate the development of next-generation new drugs," presenting antibody-drug conjugates (ADC) and multi-antibody new drug development as the twin engines driving Celltrion's future growth.

Celltrion plans to first introduce bio-better ADC new drugs that improve existing treatments, such as the non-small cell lung cancer treatment 'CT-P70' and bladder cancer treatment 'CT-P71,' which were first unveiled last year at World ADC. These treatments utilize the new payload (cytotoxic anticancer agent) 'PBX-7016,' co-developed through Celltrion's open innovation. PBX-7016 is known to exhibit low toxicity and high tumor growth inhibition (TGI) effects during development. Celltrion aims to develop a 'best-in-class' new drug with the most superior efficacy among treatments with the same mechanism through this platform and plans to consider applying it to other pipelines in the future.

Additionally, Celltrion announced sequential development of 'bispecific ADCs' targeting dual targets and 'dual payload ADCs' that maximize therapeutic effects through payload combinations.

Multi-antibody new drugs are also under development. Multi-antibody therapeutics are emerging as important treatment options to address unmet medical needs. Celltrion plans to focus on developing multi-antibody therapeutics that selectively act only on cancer cells or activate only under specific conditions. Currently, Celltrion is developing multi-antibody anticancer drugs such as 'CT-P72,' which has demonstrated improved off-tumor toxicity through cytotoxicity research showing clear differences between normal tissue cells and cancer cells.

The next-generation multi-antibody therapeutics to be developed will focus on 'conditionally active multispecific antibodies' that enhance safety by activating antibodies only against cancer targets, and 'immuno-oncology multispecific antibodies' that aim to maximize anticancer effects of various immune cells.

CEO Seo also revealed the annual clinical trial plans for new drug candidates. By 2028, Celltrion expects to submit INDs for a total of 13 candidates: 9 in the ADC field and 4 in the multi-antibody field. ADC new drugs CT-P70, CT-P71, CT-P73, and multi-antibody new drug CT-P72 will complete IND submissions this year. Next year, submissions for 2 ADC new drugs and 2 multi-antibody new drugs are planned, followed by 3 ADC new drugs in 2027, and 1 ADC new drug and 1 multi-antibody new drug in 2028.

Seo emphasized, "This year, only two years after the full-scale start of next-generation new drug development, four new drug candidates will sequentially enter clinical trials, and new drug projects will continue every year. The lead candidates have shown exceptional development speed and results from preclinical stages, so Celltrion's goal to become a global new drug company will rapidly become a reality."

During the subsequent Q&A session, Jungjin Seo, Chairman of Celltrion Group, personally presented. Chairman Seo said, "We plan to continuously pursue the development of various new drugs, including biosimilars, so that many patients can access biopharmaceuticals at reasonable prices. Based on the rapidly expanding product portfolio, we will enhance the company's future value and transform into a global new drug developer, continuing the high growth that investors expect."

Meanwhile, JPM, held from the 13th to the 16th (local time) in San Francisco, California, USA, is the world's largest pharmaceutical and bio-industry investment event, marking its 43rd edition this year.